AJP - GI Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 282: G581-G585, 2002; doi:10.1152/ajpgi.00508.2001
0193-1857/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auwerx, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auwerx, J.
Vol. 282, Issue 4, G581-G585, April 2002

THEME
Nuclear Receptors
I. PPARgamma in the gastrointestinal tract: gain or pain?

Johan Auwerx

Institut de Génétique et Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut Nationale de la Sauté et de la Recherche Médicale, Université Louis Pasteur, 67404 Illkirch, France

The peroxisome proliferator-activated receptor gamma (PPARgamma ) has recently been implicated in the pathogenesis of inflammatory bowel disease (IBD) and colon cancer. The observation that PPARgamma agonists, through immune modulation, protect against inflammatory processes in the intestine justified their expedient evaluation in the clinical management of IBD. PPARgamma agonists are reported to have both tumor-promoting and -inhibiting effects in models of colon cancer. These differences can, in part, be explained by PPARgamma -independent effects of PPARgamma agonists and by differences in the models used. Because it is still unclear how PPARgamma impacts on colon cancer, careful monitoring of patients receiving PPARgamma agonists and additional basic research is indicated before recommendations on the use of PPARgamma ligands in colon cancer can be made.

cancer; inflammatory bowel disease; hepatitis; nuclear receptors; thiazolidinediones


This article has been cited by other articles:


Home page
 GutHome page
A. De Gottardi, A. Hadengue, and J.-M. Dumonceau
Retinoids, bile acids and PPARs in Barrett's oesophagus
Gut, January 1, 2008; 57(1): 137 - 137.
[Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
H. L. Keen, M. J. Ryan, A. Beyer, S. Mathur, T. E. Scheetz, B. D. Gackle, F. M. Faraci, T. L. Casavant, and C. D. Sigmund
Gene expression profiling of potential PPAR{gamma} target genes in mouse aorta
Physiol Genomics, June 17, 2004; 18(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W K Leung, A H C Bai, V Y W Chan, J Yu, M W Y Chan, K-F To, J-R Wu, K-K Chan, Y-G Fu, F K L Chan, et al.
Effect of peroxisome proliferator activated receptor {gamma} ligands on growth and gene expression profiles of gastric cancer cells
Gut, March 1, 2004; 53(3): 331 - 338.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online